Della Vittoria Scarpati, GiuseppinaFusciello, CelestePerri, FrancescoSabbatino, FrancescoFerrone, SoldanoCarlomagno, ChiaraPepe, Stefano2014-03-112014Della Vittoria Scarpati, Giuseppina, Celeste Fusciello, Francesco Perri, Francesco Sabbatino, Soldano Ferrone, Chiara Carlomagno, and Stefano Pepe. 2014. “Ipilimumab in the treatment of metastatic melanoma: management of adverse events.” OncoTargets and therapy 7 (1): 203-209. doi:10.2147/OTT.S57335. http://dx.doi.org/10.2147/OTT.S57335.1178-6930http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879891Recently, “ipilimumab,” an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody, has been demonstrated to improve overall survival in metastatic melanoma. “CTLA-4” is an immune-checkpoint molecule that downregulates pathways of T-cell activation. Ipilimumab, by targeting CTLA-4, is able to remove the CTLA-4 inhibitory signal, allowing the immune system to react to cancer cells. Due to its immune-based mechanism of action, ipilimumab causes the inhibition of CTLA-4-mediated immunomodulatory effects, the enhancement of antitumor specific immune response mediated by the weakening of self-tolerance mechanisms while exacerbating the development of autoimmune diseases and immune-related adverse events, including dermatitis, hepatitis, enterocolitis, hypophysitis, and uveitis.en-USmelanomaT-cellsCTLA-4autoimmunityadverse eventsJournal Article2014-03-1110.2147/OTT.S57335